Business Wire: “Errant Gene Therapeutics, LLC (“EGT”) Pushing Clinical Trial of Potentially Curative Treatment for Beta-Thalassemia and Eventually Sickle Cell Disease”

Jan 11, 2021 | News

TAMPA, Fla.–(BUSINESS WIRE)–The technology, developed by scientists at Memorial Sloan Kettering Cancer Center (“MSKCC”), headed by Dr. Michel Sadelain and Errant Gene Therapeutics, is a one-time treatment that inserts an encoded gene into a patient’s own bone marrow stem cells restoring the production of normal hemoglobin. This technology is known as Thalagen.

View the rest of the article here

View the PDF

Contact us

Call Us

+1 (312) 441-1800

Our Locations

San Rocco Therapeutics
308 E. Emily St.
Tampa, FL 33603


Get in touch